Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2018 · 10-Q
Revenue$1.12M$1.12Mno prior Q1 2017 on file Net Income-$30.23M-$30.23MN/M vs Q1 2017 EPS Diluted-$0.98-$0.98N/M vs Q1 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Operating Cash Flow-$21,872,000N/M Free Cash Flowderived-$22,170,000N/M Margins · derivedGross margin13.5%
Operating margin-2768.2%
Net margin-2703.8%
ended Mar 31, 2018 · filed May 8, 2018 · 38 d after period end